Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
41°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
49.13
-0.23 (-0.47%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sanofi-Aventis S.A. ADR
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
Nasdaq, S&P 500 Eye Rebound While Bitcoin Edges Down: Amazon's Q3 Lifts Tech Stocks As Traders Eye Fed's Favorite Inflation Gauge
October 27, 2023
As Amazon, Inc. (NASDAQ:AMZN) hawked good tidings, the negative sentiment in the equity market appears to have reversed. The recovery could be in part due to traders looking for bargains following a...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Ford, Sanofi, Enphase Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session
October 27, 2023
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Acurx Pharmaceuticals Share Price And Volume Are Surging Ahead Of Phase 2b Trial Data Release ($ACXP)
October 27, 2023
Via
AB Newswire
Topics
Death
Exposures
Death
Looking Into Sanofi's Recent Short Interest
October 26, 2023
Via
Benzinga
Preview: Sanofi's Earnings
October 26, 2023
Via
Benzinga
(SNY) - Analyzing Sanofi's Short Interest
October 09, 2023
Via
Benzinga
What's Going On With Mirati Therapeutics Stock?
October 06, 2023
Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares are trading higher Friday.
Via
Benzinga
Earnings Scheduled For October 27, 2023
October 27, 2023
Companies Reporting Before The Bell • Sanofi (NASDAQ:SNY) is projected to report quarterly earnings at $2.26 per share on revenue of $12.56 billion.
Via
Benzinga
Sanofi Stock Relative Strength Rating Jumps To 84: One To Watch
October 24, 2023
Additionally, Sanofi stock has a decent 83 Composite Rating out of 99, and an 80 Earnings Per Share Rating.
Via
Investor's Business Daily
Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space
October 23, 2023
Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases.
Via
Investor's Business Daily
Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments
October 24, 2023
EQNX::TICKER_START (NASDAQ:TCBP),(NYSE:CVM),(NASDAQ:INVO),(NASDAQ:SNY),(NYSE:PFE) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
October 22, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Amazon, Alphabet, Meta, Intel Q3 Earnings This Week: Will Mega-Caps Shatter Forecasts And Revive Market?
October 23, 2023
Factset data indicates that out of the 17% of the S&P 500 companies that have reported so far, 73% have reported positive EPS surprises.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Sanofi Bridging the Gap between the Homeless and Society via Futsal
October 17, 2023
From
sanofi-aventis Korea
Via
Business Wire
Pfizer, Sanofi's Respiratory Syncytial Virus Products Faces Insurance And Logistical Hurdles To Protect Infants
October 16, 2023
As the respiratory virus season kicks off, healthcare providers are racing against time to offer Pfizer Inc's (NYSE: PFE) vaccine, Abrysvo, to pregnant patients and Sanofi SA's (NASDAQ:
Via
Benzinga
2 Healthcare Stocks Near 52-Week Highs Still Worth Buying
October 16, 2023
These two large-cap biopharma companies could have more room to run.
Via
The Motley Fool
Week In Review: Two China Biopharmas Announce Billion Dollar Deals
October 14, 2023
MediLink Therapeutics out-licensed global rights for its antibody-drug conjugate candidate to BioNTech in a $1.1 billion agreement. Meanwhile, BioMap formed a collaboration with Sanofi in a deal with...
Via
Talk Markets
2 Surefire Stocks That Could Make You Richer
October 11, 2023
It won't happen overnight, but with these stocks, a little patience is all you need.
Via
The Motley Fool
Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Bid
October 09, 2023
Bristol Myers Squibb hopes to buy Mirati Therapeutics for up to $5.8 billion.
Via
Investor's Business Daily
Amgen's Adcomm Meeting Paves Way To Launch Boost For Mirati Therapeutics' Lung Cancer Drug: Analysts
October 06, 2023
According to a report on Thursday, French pharma company Sanofi SA (NASDAQ: SNY) is reportedly exploring a potential acquisition of cancer drugmaker Mirati Therapeutics Inc (NASDAQ: MRTX).
Via
Benzinga
Palantir And PwC Team Up To Accelerate Data-Driven Operations, OpenAI Rival Secures Billions In Big Tech Backing, Six US States Brace For Healthcare Strike: Today's Top Stories
October 04, 2023
Benzinga
Via
Benzinga
Teva Pharma Hooks Sanofi In $1.5 Billion Inflammation Deal. But Shares Tumble.
October 04, 2023
The deal leans into the emerging TL1A drug class, potentially rivaling Roivant and Merck.
Via
Investor's Business Daily
Sanofi, Teva Pledge $1.5B To Target Inflammatory Bowel Disease That Impacts Almost 10M People
October 04, 2023
Sanofi SA (NASDAQ: SNY) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) have collaborated to co-develop and
Via
Benzinga
Tiziana Advances Phase 2 Site Selection For Its Lead Clinical Program In Non-Active Secondary Progressive Multiple Sclerosis (SPMS) And The Company Prepares For Six-Month Clinical Data Update
October 04, 2023
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug c
Via
Benzinga
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
October 04, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Why Shares of Kymera Therapeutics Jumped on Tuesday
October 03, 2023
The company had a big bounce after hitting a 52-week low the day before.
Via
The Motley Fool
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
October 03, 2023
Benzinga
Via
Benzinga
Pharma Giants Sanofi, Johnson & Johnson Join Forces To Develop E.coli Vaccine
October 03, 2023
Sanofi SA (NASDAQ: SNY) struck a deal with Janssen Pharmaceuticals, a unit of Johnson & Johnson (NYSE: JNJ), to develop and commercialize the vaccine candidate for extraintestinal&nb
Via
Benzinga
AstraZeneca Settles Heartburn Treatment Lawsuit For One Of Biggest Selling Drug
October 03, 2023
AstraZeneca Plc (NASDAQ: AZN) has
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
October 02, 2023
Read the latest report on NanoViricides here
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.